Literature DB >> 3305380

Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis.

U Ganzinger, G Kleinberger, K Lenz, F Schatz, A Laggner, G Grimm.   

Abstract

The pharmacokinetics of ceftazidime and netilmicin were evaluated under septicemic conditions. In a longitudinal study, both drugs were administered simultaneously (ceftazidime 2.0 g 20 min constant i.v. infusion and netilmicin 150 mg i.v. bolus injection) every 12 hours to patients who had a positive blood culture and hyperdynamic circulatory functions. Twenty-four hours after the first period of this pharmacokinetic study, identical parameters were evaluated under dipyrone induced normothermic conditions. The mean residence time and the volume of distribution was significantly altered during septicemia compared to normal conditions. With respect to the relative distribution properties ceftazidime tended to be distributed to a greater extent to the tissue compartment, whereas netilmicin showed an opposite behaviour. Beside significant correlations of absolute values, i.e. blood volume vs. volume of distribution, and relative values, i.e. total peripheral resistance vs. extraction rate, all other attempts failed to show any meaningful correlation. Owing to the heterogenous alterations of metabolic and hemodynamic functions and pharmacokinetic parameters, respectively, the data gained from this study do not allow any statistically validated conclusion regarding the pathophysiological mechanisms involved, although these findings are in accordance with animal experiments.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3305380

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  9 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  Disposition of ceftazidime in surgical patients with intra-abdominal infection.

Authors:  K L Heim-Duthoy; M P Bubrick; D M Cocchetto; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

4.  Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.

Authors:  K Heim-Duthoy; G Peltier; W Awni
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

6.  Pharmacokinetics of cefonicid in patients with skin and skin structure infections.

Authors:  K L Heim-Duthoy; G L Peltier; D R Guay; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

7.  Pharmacokinetics of cefepime in patients with respiratory tract infections.

Authors:  J M Kovarik; J C ter Maaten; C M Rademaker; M Deenstra; I M Hoepelman; H C Hart; G R Matzke; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

8.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 9.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.